Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

Trial Profile

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NabucCO
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Jan 2018 Results (n=84) assessing efficacy and tolerability of first-line therapy with paclitaxel + irinotecan + folinic acid + fluorouracil (FOLFIRI), versus paclitaxel + oxaliplatin + folinic acid + fluorouracil (FOLFOX), in patients with metastatic pancreatic cancer, were presented at the 2018 Gastrointestinal Cancers Symposium.
    • 02 Feb 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top